A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01757262 |
Recruitment Status
:
Withdrawn
First Posted
: December 28, 2012
Last Update Posted
: May 13, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Coronary Heart Disease | Drug: 90 mg Ticagrelor Drug: 75mg Clopidogrel | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patients With Coronary Heart Disease: A Randomized, Open Label, Crossover Study |
Study Start Date : | January 2013 |
Estimated Primary Completion Date : | April 2013 |
Estimated Study Completion Date : | April 2013 |
Arm | Intervention/treatment |
---|---|
Experimental: Ticagrelor
90 mg Ticagrelor
|
Drug: 90 mg Ticagrelor
Morning and Evening dose for 5 days
|
Active Comparator: Clopidogrel
75mg Clopidogrel
|
Drug: 75mg Clopidogrel
Morning dose for 5 days
|
- Pharmacodynamics of Ticagrelor on P2Y12 receptor blockade measured by the VerifyNow P2Y12 assay[expressed as P2Y12 reaction units (PRU)] [ Time Frame: Day 1 pre-dose and at 0 (pre-dose), 1, 2, 8, 12 and 24 hours post morning dose on Day 5 ]
- Pharmacodynamics of Clopidogrel P2Y12 receptor blockade measured by the VerifyNow P2Y12 assay[expressed as P2Y12 reaction units (PRU)] [ Time Frame: Day 1 pre-dose and at 0 (pre-dose), 1, 2, 8, 12 and 24 hours post morning dose on Day 5 ]
- Safety profile in terms of adverse events, blood pressure, pulse, ECG (Electrocardiogram), physical examination, and safety laboratory variables [ Time Frame: From screening to followup (8 weeks) ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female Vietnamese patients (as confirmed by the Principal Investigator) aged >18 years with suitable veins for cannulations or repeated venipunctures and stable coronary heart disease
- Stable use of aspirin 75 to 100 mg daily for at least the preceding 2 weeks and which will be continued throughout the study period
- Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive
- Women must have a negative urine pregnancy test at Visit 1
Exclusion Criteria:
- History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study
- Unstable angina or any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IP
- Patients who had acute coronary syndrome or stent placed within 12 months of screening
- Planned arterial revascularization
- Current use of ADP receptor blockers (eg, clopidogrel, ticlopidine, prasugrel), dipyridamole or cilostazol

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01757262
Principal Investigator: | Nguyen Lan Viet, MD | National Heart Institute, Bach Mai Hospital, Vietnam | |
Study Director: | Judith Hsia, MD | Astrazeneca, Wilmington, US | |
Study Chair: | Miriana Kujacic, MD | Astrazeneca, Molndal, Sweden |
Responsible Party: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT01757262 History of Changes |
Other Study ID Numbers: |
D5130C00078 |
First Posted: | December 28, 2012 Key Record Dates |
Last Update Posted: | May 13, 2013 |
Last Verified: | May 2013 |
Keywords provided by AstraZeneca:
Coronary Heart Disease |
Additional relevant MeSH terms:
Heart Diseases Coronary Disease Coronary Artery Disease Myocardial Ischemia Cardiovascular Diseases Vascular Diseases Arteriosclerosis Arterial Occlusive Diseases Clopidogrel Ticlopidine Ticagrelor Platelet Aggregation Inhibitors |
Purinergic P2Y Receptor Antagonists Purinergic P2 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Fibrinolytic Agents Fibrin Modulating Agents Cytochrome P-450 CYP2C19 Inhibitors Cytochrome P-450 Enzyme Inhibitors Enzyme Inhibitors |